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In recent years, cancer stem cells (CSCs)/tumor initiating
cells (TICs) have been identified inside different tumors.
However, currently used anti-cancer therapies are
mostly directed against somatic tumor cells without
targeting CSCs/TICs. CSCs/TICs also gain resistance to
chemotherapies/radiotherapies. For the development of
efficient treatment strategies, choosing the best
method for isolation and characterization of CSCs/TICs
is still debated among the scientific community. In this
review, we summarize recent data concerning isolation
techniques for CSCs using magnetic cell sorting and
flow cytometry. The review focuses on the strategies for
sample preparation during flow cytometric analysis,
elaborating biomarkers such as CXCR4, CD105, and
CD133. In addition, functional properties characteristic
of CSCs/TICs using side population selection through
Hoechst 33342 dye, aldehyde dehydrogenase 1,
dye-cycle violet, and rhodamine 123 are also discussed.
We also include a special focus on enriching CSCs/TICs
using three-dimensional cell culture models such as
agarose–agarose microbeads and sphere formation.cells from minced tissue were subjected to further stem cell
characterization studies. The frequency of CD105+ cells inIntroduction
The identification of adult cancer stem cells (CSCs) in
cancerous tissues prompted researchers to understand their
role in carcinogenesis. Some cancer cells are more potent
than others because of malignancies that arise from either
the mutation of normal stem cells or tumor cells that
acquire stem cell-like characteristics. CSC theory suggests
that these small populations of cells can reproduce and
sustain cancer even after subsequent treatment, act more* Correspondence: imrankhanbioinfo@gmail.com
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specialized cells are termed CSCs or, more broadly, tumor
initiating cells (TICs). Furthermore, research has shown
that CSCs/TICs not only exhibit characteristics of normal
stem cells, but also gain greater resistance to chemother-
apies/radiotherapies. Isolation and further characterization
of CSCs/TICs still hold vast mystery among the scientific
community owing to a lack of specific stem cell markers.
Another difficulty is in determining the methodology
employed in isolating CSCs/TICs. In this review, we
summarize recent data concerning CSCs/TICs cell isolation
techniques and markers for human renal cell carcinoma
(RCC).Stem cell surface markers in RCC
CD105 is a receptor for transforming growth factor (TGF)
located on cell surfaces and takes part in TGF-β signaling
by interacting with TGF-β receptors I and/or II. CD105 is
important for angiogenesis and is also a prominent marker
for mesenchymal stem cells (MSCs) [1]. Bussolati et al. [2]
first derived CD105+ cells, as TICs, from patient specimens
after radical nephrectomy. Magnetically sorted CD105+
this study was 8.06 ± 3.3 % and the cells were able to in-
duce tumors in all mice with injected CD105+ cells. These
results were in agreement with the CSC/TIC hypothesis
(Table 1). Moreover, cells with the CD105 marker had
much stronger features of CSCs/TICs compared with cells
without CD105. The presence of CD105+ cells has also
been demonstrated in established RCC cell lines 786-O,
SMKTR2, SMKTR3, 769-P, Caki-1, Caki-2, ACHN, and
RCC-6 [3, 4]. Isolated CD105+ cells were further examined
for other human MSC markers using the BD Stemflow™
hMSC analysis kit (BD Biosciences, Franklin Lakes, New
Jersey, USA). These cells had increased expression of
CD73 and CD90 markers and decreased expression of
CD44 and CD146. After culturing for 5 days, however, re-distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Comparison of methods for CSC/TIC isolation
Putative markers examined Isolation method Cell selection method Cell lines/specimens examined Examined CSC/TIC criteria Reference




Not examined ALDH1 Flow cytometry Ovary: AMOC-2, HUOA,
OVCAR-3, ES-2, RMG-1, TOV-21G




ABCB1, ABCG2, ABCC1 Hoechst 33342 Flow cytometry Renal: 769P, 786-O, OS-RC-2,
SN12C, SKRC39




Sox-2, POU5F1, Cdh1, Cdh2, Snai1, Snai2,
Twist1, Twist2
Hoechst 33342 Flow cytometry Renal: RENCA, ACHN, CAKI-1,
SMKT-R2, SMKT-R3
In-vivo tumorigenicity Nishizawa et al.,
2012 [23]
CD3, CD4, CD8, CD24, CD44 Rhodamine Flow cytometry Renal: 786-O Colony formation assay, radiation sensitivity
assay, in-vivo tumorigenicity
Lu et al., 2013 [21]
CD24, CD44, CD31, CD146, CD90, CD73,




Magnetic-activated cell sorting Renal carcinoma specimens Sphere formation assay, in-vivo tumorigenicity Bussolati et al.,
2008 [2]
CD34, CD45, CD14, CD44, CD29, CD73,




Magnetic-activated cell sorting Renal carcinoma specimens In-vivo tumorigenicity Bruno et al., 2006 [8]
CD24, CD29, CD44, CD73, CD146, CXCR1,
CD34, CD90, CD105, CD133, ALDH1,




Flow cytometry Renal: RCC-26, RCC-53,
SK-RC-17
In-vivo tumorigenicity, sphere formation
assay, drug sensitivity assay
Gassenmaier et al.,
2013 [14]
CD44, CD24, Sca1, Oct-4, Wnt,
ABC white 2, β-Catenin,
Encapsulation of
tumor colony
Cell recovery from 3D culture
inside macrobeads
Renal: RENCA Not examined Smith et al.,
2011 [66]







Cell recovery from 3D culture
inside macrobeads




CD133, CD34, CD24, CD14, CD105,




Flow cytometry ccRCC specimens In-vivo tumorigenicity, chemotherapy sensitivity
assay, cell cloning and differentiation assay
Galleggiante et al.,
2014 [9]
Oct-3/4, Nanog, Pax-2 ALDH1 Flow cytometry Renal carcinoma specimens In-vivo tumorigenicity, sphere formation
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of the cells were able to maintain the CD105 antigen, sug-
gesting that CD105+ cells are highly differentiating and
transient in nature [4].
CD133, also called Prominin-1 or AC133, is a pentaspan
transmembrane protein first identified in mouse neuroepi-
thelial stem cells and later described in human
hematopoietic stem cells [5, 6]. The CD133+ cell popula-
tion has been identified as resident renal progenitor cells
in adult normal human kidney [7] and contributes to
tumor vascularization and angiogenesis. Bruno et al. dem-
onstrated a contributory role of CD133+ progenitor cells
derived from human RCC in tumor vascularization [8].
CD133+ and CD133− cells were magnetically sorted using
the magnetic-activated cell sorting (MACS) system to
evaluate in-vivo angiogenesis and tumorigenic potential.
CD133+ or CD133− cells were transplanted into SCID
mice with or without cells from the K1 RCC cell line at
different ratios (i.e., 1:100 for CD133+/K1 cells, 100:1 for
CD133+/K1 cells). Results were compared with mice
injected with K1 cells alone (1 × 104 to 1 × 106 cells).
Injected CD133+ cells alone did not form tumor after
6 months. However, CD133+ cells cotransplanted with the
RCC cell line K1 significantly enhanced tumor growth and
development. Moreover, newly formed vessels within the
tumor were positive for both human HLA class I and hu-
man CD31, confirming its human origin. The fact that
tumor vessels were derived from differentiating CD133+
progenitor cells plus K1 cells was later confirmed by fluor-
escence in-situ hybridization for expression of human
chromosome X [8]. Others have identified CD133+ cells
that coexpressed CD24 and CTR2 antigens from RCC pa-
tients [9]. CD133+/CD24+/CTR2+ cells were more tumori-
genic and have more potential to behave as CSCs/TICs
compared with cells which do not express these markers.
CXCR4 chemokine receptor belongs to the superfam-
ily of G protein-coupled receptors and has been found
to be a prognostic marker in various types of human
cancer. The chemokine CXCL12 (SDF-1) acts as a
chemoattractant to the CXCR4 receptor-positive pri-
mary tumor cells, and drives them toward secondary
metastatic sites. CXCL12–CXCR4 axis signaling is
known to play a pivotal role in the homing of normal
stem cells [10]. Interestingly, CSCs have been found to
express CXCR4 receptor, and this CXCL12–CXCR4 axis
is also involved in trafficking/metastasis of CSCs to the
organs which are highly rich in CXCL12, such as the
lymph nodes, lungs, liver, and bones [11, 12]. Schrader
et al. analyzed the CXCL12/CXCR4 expression and func-
tion in four human RCC cell lines: A-498, Caki-1, Caki-2,
and HA-7 [13]. Cell surface expression analysis of CXCR4
antigen using fluorescence-activated cell sorting (FACS)
showed that only Caki-1 and A-498 cell lines expressed
this antigen, which was also confirmed through RT-PCR.Another breakthrough study [14] identified the pivotal
role of CXCR4 receptor in maintaining cancer stem-like
features and metastasis particularly in relation to RCC.
The study examined two RCC lines, RCC-26 and RCC-53,
derived from primary tumors of clear cell RCC (ccRCC)
patients with disease stage I and IV, respectively. These
differ significantly in their capability of forming tumor
spheres. Under nonadherent conditions, RCC-56 cells
form numerous spheres compared with RCC-26 cells,
which form rather poor spheres. Flow cytometry analysis
after dissociation of spheres demonstrated an increased
fraction of CXCR+ cells in a prosphere culture condition
compared with a monolayer culture environment. In
addition, sorted CXCR+ cells from both cell lines have in-
creased expression for stemness genes, such as Nanog,
Oct-3/4, and Sox-2, and higher resistance to tyrosine kin-
ase inhibitors, such as sunitinib, sorafenib, and pazapanib
[14].
CD44 is a single-chain transmembrane glycoprotein
that has a major role as an adhesion molecule for the
extracellular matrix which binds primarily to the extra-
cellular glycosaminoglycan hyaluronan [15, 16]. CD44, a
cell surface antigen, has been implicated in a wide var-
iety of physiologic processes including wound healing,
cell growth, survival, and differentiation as well as tumor
cell migration, invasion, and metastasis. Some have also
reported CD44 as CSCs/TICs [16, 17], although this na-
ture is still controversial [18] (Table 2). Furthermore,
clinical data have also suggested positive correlation be-
tween CD44 expression and metastasis [19]. Debeb et al.
[20] described several features of CD44+/CD24− cells as
CSCs/TICs which were derived from the human embry-
onic kidney cell line 293T. In-vivo observation of serially
transplanted 293T cells showed self-renewal and sphere
formation when cultured in a stem cell-promoting sus-
pension culture. Moreover, CD44+/CD24− cells showed
increased aldehyde dehydrogenase (ALDH) activity in
three-dimensional culture compared with two-dimensional
cell culture conditions. Furthermore, the three-dimensional
spheres from CD44+CD24− cells were resistant to chemo-
therapy and radiotherapy [20]. These findings suggest the
importance of CD44+CD24− cells as CSCs/TICs, but the
underlying mechanisms are unclear. Similar results were
also reported in Rh123high sorted cells and spheres from
ccRCC cell lines 786-O, ACHN, and Caki-1 [21, 22] and
in CD105+ cells isolated from RCC specimens [2].
Intracellular markers in RCC
Heat shock protein (HSP) 40 family member DnaJ
(Hsp40) homolog, subfamily B, member 8 (DNAJB8) has
an important role in maintaining the CIC/TIC pheno-
type in RCC and colon cancer [23, 24]. Overexpression
of DNAJB8 enhances the expression of stem cell
markers and tumorigenicity. The human RCC cell lines
Table 2 Marker-based RCC CSC phenotypes
Marker (positive) Sox, Oct, Nanog,
Bmi-1
EMT markersa Spheres Mice Cell line RCC type Reference
CD44, CD49f, ALDH1, CD24↓ + E↓, M↑+/− –, ROS + Caki-1 ccRCC Mahalingaiah et al., 2015 [17]
CD24, CD44 + M↑ + – ACHN, Caki-1 pRCC, ccRCC Lichner et al., 2014 [22]
– + E↓, M↑ +, TNFα – ACHN, 786-0 pRCC, ccRCC Zhang et al., 2014 [27]
DCLK1↑ ALDH1 + M↑ – – Caki-2 pRCC Weygant et al., 2015 [29]
CD44, CD133, CXCR4 NS, B-cathenin M↑ +, PIK3R1↓ – 786-0, A-704 ccRCC, RCC Lin et al., 2015 [30]
ALDH1 + – – + Caki-2, ACHN pRCC, pRCC Wang et al., 2015 [63]
CXCR4, CD105↓, CD133(−)b + – + + RCC-26, RCC-53 RCC Gassenmaier et al., 2013 [14]
CD24, CD44, CD133(−), CD105(−) + B-c↑ + + SK-RC-42 RCC Zhong et al., 2010 [72]
CD24, CD44 Side population – + + 786-0 ccRCC Lu et al., 2013 [21]
ALDH1 – NS + + ACHN pRCC Ueda et al., 2013 [45]
aMesenchymal (M): vimentin, N-cadherin, fibronectin, Snail, Fox-2, Slug, ZEB1. Epithelial (E): E-cadherin, cytokeratin, B-catenin
bCD24, CD29, CD44, CD73, CD146—highly expressed on cell line = not considered as CSC markers
↓ decrease, ↑ increase, ALDH aldehyde dehydrogenase, B-c B-catenin, ccRCC clear cell renal cell carcinoma, CSC cancer stem cell, EMT epithelial–mesenchymal
transition, NS not specified, pRCC papillary renal cell carcinoma, RCC renal cell carcinoma, ROS reactive oxygen species, TNFα tumor necrosis factor alpha
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gether with murine RENCA cells and BALB/3 T3 cells
from murine fibroblasts were analyzed for expression of
DNAJB8 [23]. The ratio of side population (SP) cells de-
rived from ACHN and RENCA cells was 2.6 % and
18 %, respectively, using Hoechst 33342 dye staining.
RT-PCR analysis of these isolated SP cells showed that
DNAJB8 was predominantly expressed together with
Sox-2 and POU5F1 genes. Western blotting and immuno-
staining using SP cells also correspond with preferential
expression of DNAJB8 protein, confirming stem cell-like
phenotypes [23].
Micro RNAs (miRNAs) are small, noncoding, single-
stranded RNA molecules that act as posttranscriptional
regulators. They are required for the maintenance of
normal pluripotent embryonic stem cells in mice [25].
The role of miRNAs has been documented in many can-
cers, including breast cancer, glioblastoma, and prostate
cancer [26]. In RCC, Lichner et al. [22] examined the in-
fluence of miR-17 on cancer spheres with cancer stem-
like properties from two metastatic RCC cell lines:
ACHN and Caki-1. Spheres were obtained from ACHN
and Caki-1 cells while cultured in serum-free defined
media (SFDM) supplemented with fibroblast growth fac-
tor (FGF), epidermal growth factor (EGF), and B27.
Sphere-forming cells were later examined for CD24 and
CD44 CSC markers. Spheres from Caki-1 and ACHN
cell lines were positive for CD24+/CD44+ at 10 % and
9.37 %, respectively. In addition, spheres from both cell
lines exhibited greater tumorigenic ability and increased
expression for stem cell and mesenchymal markers
in vivo. However, miR-17 was significantly downregu-
lated in both cell lines. Transfection with anti-miR-17
led to a rapid formation of three-dimensional spheres
but did not affect the sphere-forming efficiency.Interestingly, miR-17 inhibition resulted in 2.4-fold and
1.96-fold increase in the number of colonies formed in
Caki-1 and ACHN, respectively, demonstrating capabil-
ities of inducing self-renewal and significantly increased
expression for mesenchymal markers such as ZEB1, ZEB2,
vimentin, and N-cadherin and for cancer stem markers
CD24 and CD44 [22].
Emerging evidence suggests that acquisition of epithe-
lial–mesenchymal transition (EMT) is associated with
tumor invasion and metastasis. EMT plays an important
role in tumor progression via an acquired ability to self-
renew, spread, and recur. Together, these features of
EMT strongly suggest a possible relationship with the
CSC phenotype. In a recent study, the EMT process was
artificially induced inside the cell culture of RCC cell
lines ACHN and 786-O to enrich their stemness features
[27]. ACHN and 786-O cells were treated with 50 ng/ml
tumor necrosis factor alpha for 7 and 14 days, respectively.
This led to a loss of epithelial morphology and acquired
mesenchymal appearance, and increased expression of
mesenchymal protein markers such as Vimentin, Slug,
and ZEB1. In addition, these EMT signature RCC cells
had upregulation of stemness genes such as Oct-4, Nanog,
and Bmi-1, together with increased potential of tumor
sphere formation [27].
In contrast to artificially induced EMT, Li et al. [28]
applied a different approach which can reverse the EMT
process and inhibit CSC-like characteristics in RCC.
Honokiol extracts isolated from Magnolia spp. bark can
suppress the proliferation of RCC cells in vitro. Further-
more, there can be an increase in protein expression of
epithelial markers E-cadherin and decrease in expression
of mesenchymal markers such as fibronectin and
Vimentin. Honokiol significantly decreases the number
and size of tumor sphere formation and decreases the
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honokiol regulates EMT and CSC/TIC properties by
modulation of miR-141 and its target gene ZEB2 [28].
Analysis of The Cancer Genome Atlas’ Kidney Renal
Clear Cell Carcinoma (TCGA KIRC) dataset revealed
that Doublecontin-like kinase 1 (DCLK1) is epigenetically
overexpressed in RCC tumors regardless of the disease
stage [29]. Recently, Weygant et al. [29] investigated the
importance of DCLK1 in regulation of EMT and main-
taining stemness features. Silencing of the DCLK1 gene
using DCKL1 small interfering RNA (siRNA) in primary
RCC-caki-2 cells resulted in decreased expression of EMT
transcriptional factors (SNAI1, SNAI2, TWIST1, ZEB1,
and Vimentin). Moreover, this gene silencing also led to
reduced expression of stemness and pluripotency factors
MYC, Nanog, Oct-4, Sox-2, and ALDH1A1. These results
illustrate the vital role of DCLK1 knockdown in reducing
the invasive and metastatic capability of RCC. High pro-
tein expression of PIK3R1 has been observed in normal
kidney tissues. Recent findings showed that PIK3R1 ex-
pression correlated with RCC progression and metastasis
[30]. Functional study of PIK3R1 knockout revealed its
significant role in RCC cell migration and proliferation
[30]. Moreover, knockout PIK3R1 cells displayed a mesen-
chymal morphology and increased expression for EMT-
related factors in vitro.
Multiple marker phenotype of RCC CSCs
Coexpression of multiple putative stem markers in iden-
tifying CSCs has been studied in many cancers [31, 32].
Recently, Galleggiante et al. [9] identified cancer stem-
like cells using the multiple marker CTR2+/CD133
+/CD24+ from patients with clear RCC. This resident
subpopulation showed stemness properties similar to
tubular adult renal progenitor cells (tAPCs) derived from
healthy kidney. CD133+/CD24+ cells isolated from
tumor kidney tissue were more undifferentiated than
tAPCs. CTR2 is localized on the cell surface membrane
and coexpressed with CD133+/CD24+ cells. Expression
of CTR2 has been reported by others in human RCC.
Coexpression of CTR2 with CD133/CD24 protein could
be useful in discriminating between CSCs and the nor-
mal renal cell population [9]. Moreover, in RCC patients
a significant role of CTR2 in cisplatin-based resistance
also been reported. Another example of a coexpression
approach is to identify CSCs in RCC using CD133/
CXCR4-based cell selection. Resistance to sunitinib is a
major obstacle in RCC treatment [33]. Varna et al. [34]
studied the role of CD133+/CXCR4+ cells in the course
of developing such resistance. RCC specimens obtained
from patients before and after sunitinib treatment were
analyzed for cells expressing CD133. CD133-expressing
cells were significantly more numerous in sunitinib-
treated patients than in untreated patients. Interestingly,CD133+ cells coexpressed CXCR4, which showed higher
tumorigenic potential in vitro [34].Methods for the isolation of cancer stem-like cells
Cluster of differentiation identification
Another well-known method for stem cell separation is
MACS. This widely used method isolates different types
of cells including human lymphocytes, dendritic cells,
mega-karyotic cells, and granulocytes [35–38]. The use
of small magnetic beads conjugated with antibodies al-
lows for direct enrichment and isolation of cells without
further staining. Bussolati et al. [2] used this method to
isolate tumor-initiating cells in specimens from RCC
obtained after radical nephrectomy. Specimens were
minced and digested using collagenase II. They used
CD105 (endoglin) antibody conjugated with magnetic
beads that recognized surface antigens for CD105+
cells. Before isolation, 2 × 107 cells were initially labeled
using 80 μl monoclonal anti-CD105 antibody coupled
with magnetic beads in cold MACS running buffer
(phosphate-buffered saline (PBS) without Ca2+ and Mg2+
supplemented with 1 % bovine serum albumin (BSA)
and 5 mM ethylenediamine tetraacetic acid (EDTA)) for
20 min. Later, cells were washed twice using MACS buf-
fer and were suspended in MACS buffer. The cell sus-
pension was passed through a MACS magnetic column
held on the MACs separator stand. During this process,
CD105+-labeled cells are collected inside the MACS
column and can be further collected by pushing a plun-
ger into the column [2].Side population isolation
One of the most popular and commonly used methods
to identify CSCs/TICs is SP cell selection using Hoechst
33342 dye [39–41]. The SP phenotype is a manifestation
of primitive cells’ ability to efficiently efflux the fluores-
cent DNA-staining dye (i.e., Hoechst 33342) and can be
used to isolate these cells using flow cytometry [42]. This
is in contrast to the protein marker approach for isolation,
where cells are first immunostained with fluorescently con-
jugated antibodies. Later, positively fluorescent labeled cells
are sorted using flow cytometry whereas the Hoechst
33342 dye efflux assay isolates cells based on the ability of
stem cells to actively efflux cytotoxic agents like Hoechst
33342, a bis-benzimidazole that binds to adenine–
thymine-rich regions of the minor groove of DNA.
SP cells have been analyzed by this technique from healthy
hematopoietic stem cells inside bone marrow [43]. More-
over, this study showed that the SP also has exceptionally
strong features of stem cell-like activities. There are many
reports that suggest a role for CSCs/TICs in solid tumors,
but only few reports contribute toward involvement of SP
cells in RCC [23, 44–46].
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Saint Louis, USA) was used in two RCC cell lines de-
rived from primary lesions of Japanese females (KRC/Y)
and from malignant (ACHN) pleural effusion from
Caucasian males with metastatic RCC [45]. Cells were
cultured in monolayers until they reached nearly 80 %
confluence, and then cells were harvested using accutase
and suspended at a density of 1 × 106/ml in PBS with
2 % fetal bovine serum (FBS). Suspended cells were in-
cubated with Hoechst 33342 dye at 37 °C for 60 min.
The samples were washed, centrifuged, and resuspended
in 2 ml cold PBS with 2 % FBS. Propidium iodide (PI)
was then added at a concentration of 1 mg/ml to meas-
ure dead cells. Cells were filtered through a 40 μm mem-
brane. Finally, the SP cell analysis was carried out
through a FACS AriaII flow cytometer (BD Biosciences,
San Jose, CA, USA). The SP percentage in ACHN and
KRC/Y cells was 1.4 % and 1.7 %, respectively, whereas
upon treating cells with reserpine no SP cells were ob-
served. Hoechst 33342 dye staining was used for analysis
of SP cells and non-SP cells in five established human
RCC cell lines: 769P, 786-O, OS-RC-2, SN12C, and
SKRC39 [47]. This method proved effective only in the
769P cell line; in the other cell lines, the ratio of SP cells
was either too low or nondetectable. In addition, the ex-
pression of the ATP-binding cassette (ABC) transporter
ABCB1, a member of the MDR/TAP protein subfamily,
was higher in SP cells compared with non-SP cells,
which was further confirmed by RT-PCR and western
blot [47].
The ability to recognize Hoechst-positive SP cells de-
pends on the differential efflux of cells by multidrug-like
transporter protein. Great attention is therefore required
for Hoechst concentration, staining time, and staining
temperature. All steps are critical before analysis. In the
RCC cell line 769-P, SP analysis and cell isolation was
performed with a small modification as described previ-
ously by Goodell et al. [43]. The cells were mobilized
using trypsin instead of accutase, and were suspended in
prewarmed RPMI-1640 containing 2 % FBS and 10 mmol/l
HEPES [23]. RCC cells were spun down and resuspended
at 1 × 106 cells/ml in RPMI-1640, followed by standard in-
cubation with 5 mg/ml Hoechst 33342 dye at 37 °C for
90 min in the dark. After staining, cells were spun down
and resuspended in cold HBSS again containing 2 % FBS
and 10 mmol/l HEPES for flow cytometry analysis. An-
other option is to suspend cells in prewarmed Dulbecco’s
modified Eagle’s medium (DMEM) with 5 % FBS. Hoechst
33342 dye can be added at a final concentration of
2.5 mg/ml in the presence or absence of verapamil
(50 mmol/l). The cells may then be incubated at 37 °C for
90 min with intermittent blending [23].
Hughes et al. [48] also employed the Hoechst SP ap-
proach for stem cell identification from renal epithelialcells and a novel method to further characterize SP cells
using synchrotron radiation–Fourier transform infrared
(SR-FTIR) spectroscopy. In this method, renal epithelial
cells were first stained with Hoechst 33342 dye and
sorted using a FACS vantage cytometer to define the SP
gate. Thereafter, SR-FTIR spectroscopy was used to ac-
quire single-point spectra and biochemical maps for
each cell type. SP sorted cells were very small, consisting
of a nucleus and limited cytoplasm, demonstrating that
these cells have a distinct chemical phenotype compared
with the remaining renal cells [48].
Another CSC identification method is based on the
cells’ ability to efflux toxins using rhodamine 123 (Rh123),
which preferentially accumulates in active mitochondria.
The content of Rh123 dye in the cells helps to isolate cells
with progenitor characteristics [49, 50]. Rh123 is a cell-
permeable fluorescent dye that stains mitochondria in
cells, since there is a correlation between the amount of
ATP in cells, the fluorescence intensity of Rh123 dye, and
drug resistance though the ABC [51, 52]. In the human
RCC line 786-O, two different fractions of cells were ob-
served: Rh123high cells and Rh123low cells. The 786-O cell
line was first grown in RPMI-1640 media supplemented
with 10 % heat-inactivated FBS using normal incubation
conditions [21]. Once the cells reached a logarithmic
growth phase, they were harvested using 0.25 % trypsin.
Cells were washed twice with calcium/magnesium-free
PBS and resuspended in ice-cold RPMI-1640 with 5 %
FBS at a concentration of 1 × 106 cells/ml and incubated
for 10 min at 37 °C in 5 % CO2. Rh123 fluorescent dye
was added at a concentration of 10 μg/ml and incubated
for 20 min in the dark. Cells were washed twice with PBS
and examined by flow cytometry. Sorted cells were divided
into two groups: rhodamine high active cells (Rh123high)
and rhodamine low active cells (Rh123low). Rh123high has
been further assessed for other stem cell-like properties,
such as colony formation, radio-sensitivity, screening for
stem cell markers (CD24 and CD44), and tumor forma-
tion in SCID mice. The human primary RCC line 786-O
was used to isolate the CSC/TIC population based on the
Rh123 fluorescent intensity [21]. The cells with increasing
intensity for Rh123 dye exhibit characteristics of stem-like
cells that include higher colony formation capability,
higher differentiation potential, and resistance to radiation
and tumor formation in NOD/SCID mice [21].
CSCs/TICs are hypothesized to be resistant from toxins,
hypoxia, and radiation [53, 54]. One possible mechanism
behind toxin efflux is through the expression of ABC
transporter proteins. Moreover, protein overexpression of
members of the ABC transporter superfamily (ABCB1,
ABCC1, and ABCG2) contributes to drug resistance and
exhibits the SP phenotype. Hence, another method to iso-
late CSCs/TICs is based on the ability to efflux toxins
using the dye-cycle violet (DCV) cell staining procedure.
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permeable dye in identifying the SP in bone marrow and
cultured cell lines of prostate cancer [51, 55, 56]. However,
the role of DCV in CSC identification in RCC is still un-
tested and not enough data have been reported. DVC is
an alternative to Hoechst 33342 dye staining and is also a
substrate for the ABCG2 efflux transporter protein that
can be excited by a violet laser. Samples were prepared in
suspension and Fumitremorgin C (FTC) was used to in-
hibit ABCG2 function to facilitate localization of DVC
effluxing cells in prostate cancer [56, 57]. In darkness, 1 μl
DVC was added to 1 × 106 cells in 0.5 ml epithelial culture
media with or without 0.5 μl FTC [56]. Sample tubes were
vortexed and incubated at 37 °C for 20 min. After 20 min,
samples were vortexed and 1 μl DVC was added again to
obtain a final concentration of 10 μM. Samples were again
incubated at 37 °C for 90 min and vortexed every 15–20
min during incubation. Later, samples were centrifuged at
800 × g for 5 min at 4 °C and washed with 1× PBS before
resuspension in 0.5 ml Hanks solution with 5 % FBS buffer.
Finally, 5 μl of 7-aminoactinomycin D (7AAD) was added to
the samples in the dark. Cells were sorted using FACS [56].
Aldehyde dehydrogenase identification
ALDH1 is an enzymatic approach for both normal stem
cell and CSC/TIC identification. Researchers have used
the ALDEFLUOR assay where high expression of ALDH1
enzyme activity corresponds to CSC/TIC markers in dif-
ferent types of cancer, including lung cancer, prostate can-
cer, breast cancer, bladder cancer, liver cancer, ovarian
cancer, and malignant melanoma [58–63]. Ueda et al. [45]
researched the biological features of ALDH1+ and ALDH1
− in samples prepared from SP and non-SP cells, drug-
treated cells, and cells cultured under hypoxic conditions
previously isolated from two RCC cell lines. SP and non-
SP cells were cultured for 72 h. Later, samples were sus-
pended in ALDEFLUOR assay buffer containing ALDH
substrate with 50 mg dry bodipy-aminoacetaldehyde, with
or without 5 μl ALDH inhibitor (diethylaminobenzalde-
hyde) as a negative control. Samples were incubated for
60 min at 37 °C inside the incubator prior to analysis
using flow cytometry. An almost twofold increase of
ALDH1+ cells was observed in the metastatic ACHN cell
line (15.3 %) compared with the primary KRC/Y cell line
(6.5 %). This research demonstrated that the number of
ALDH1+ SP cells (32.7 %) was double that of non-SP cells
(14.6 %). In addition, the sphere-forming ability of ALDH+
cells was higher in both RCC cell lines compared with
ALDH− cells and RCC cells were capable of forming tu-
mors in mice [45].
Three-dimensional cell culture
The three-dimensional culturing of tumor cells can be
used to closely mimic the in-vivo tumor microenvironment,unlike the traditional two-dimensional monolayer culture
[64]. This novel three-dimensional culturing model for
tumor cells in polymeric scaffolds was first discussed by
Jain et al. [65]. In RCC, this method was employed to en-
rich the cancer stem-like cells from the mouse renal
adenocarcinoma RENCA cell line using macrobeads [66].
RENCA cells were grown for 5 days inside six-well plates
at a density of 15,000 cells per well containing 10 % neo-
natal calf serum (NCS) in RPMI-1640 media. Separately,
100 μl of 0.8 % low-viscosity agarose was prepared in
minimum essential medium (MEM), and kept at 51–53 °C
followed by mixing with 1.5 × 105 RENCA cells. The agar-
ose cell suspension was expelled into sterile mineral oil at
room temperature to form a smooth, semi-solid core of
macrobeads. Mineral oils were removed with RPMI-1640
and the core was cultured overnight at 37 °C under 5 %
CO2. The following day, the core was rolled in a sterile
spoon containing 1 ml of 4.5 % agarose in MEM main-
tained at 61–63 °C to apply an outer coating of agarose.
These agarose–agarose macrobeads were transferred to
mineral oil to form smooth macrobeads and washed
again with RPMI-1640 prior to culture. Macrobeads
were cultured at 37 °C in 5 % CO2 in a 90-mm Petri dish
containing 10 macrobeads in 40 ml of 10 % NCS-
supplemented RPMI-1640 media. Immunofluorescence
studies on RENCA macrobeads show enrichment of
CSC/progenitor cell-like attributes [66]. These cells
tested positive for CD44 (CD24−), stem cell antigen-1
(SCA-1), and OCT4 protein.
Culturing conditions for CD105+ clones to grow as a
floating tumor sphere were first modified by Bussolati
et al. [2]. Cells were plated at 1 × 103 cells/ml in serum-
free DMEM/F12 with 10 ng/ml basic FGF and 20 ng/ml
EGF together with 5 μg/ml insulin and 0.4 % BSA.
Spheres were further dissociated using nonenzymatic so-
lution every 7–10 days to evaluate signal cell sphere for-
mation. Gassenmaier et al. [14] obtained tumor spheres
from two RCC cell lines derived from primary tumors of
ccRCC patients with disease stage I (RCC-26) and stage
IV (RCC-53). Tumor spheres were formed in serum-free
medium consisting of DMEM/F12, 1 % insulin–transfer-
rin–selenium-X, 2 % B27, 20 ng/ml EGF, and 20 ng/ml
basic FGF. Cells were seeded in low attachment plates
and grown for up to 7 days. The number of spheres was
assessed after 4 days to avoid miscalculation connected
with aggregates of spheres [14].
Modification of the cell culture technique to obtain
CD105+ cells from floating tumor spheres has been
demonstrated by Hu et al. [67]. In their method, cultures
were disrupted into single cells using a 37 μm filter, and
cultured in 96-well plates with a low adhesion surface.
The cells were added to each well at a concentration of
300–500 cells/well. Cultures were fed with serum-free
medium supplemented with N2 (1:100), heparin (5 g/ml),
Khan et al. Stem Cell Research & Therapy  (2015) 6:178 Page 8 of 11EGF and basic FGF (both 20 ng/ml), insulin (20 ng/ml),
B27 (1 %), and human leukemia inhibitory factor
(100 ng/ml) [67].
Spheres were obtained from ACHN and Caki-1 cells
while culturing in SFDM supplemented with FGF, EGF,
and B27. Spheres from those Caki-1 and ACHN cell
lines were positive for CD24+/CD44+ at 10 % and
9.37 %, respectively [22]. In addition, spheres from both
cell lines exhibited greater tumorigenic ability and in-
creased expression for stem cell and mesenchymal
markers in in-vivo studies, demonstrating capabilities of
inducing self-renewal and significantly increased expres-
sion for mesenchymal markers such as ZEB1, ZEB2,
vimentin, and N-cadherin, and cancer stem markers
CD24 and CD44 [22].
Serum-free culture-based approach
In 1992, Reynolds and Weiss [68] developed the sphere
culture method with cells isolated from adult mamma-
lian brain. This method has since been employed to iso-
late cells with CSC/TIC characteristics. Many studies
confirmed that under serum-free conditions and in the
presence of specific mitogens, such as EGF and basic
FGF, the CSC/TIC population can be enriched [69–71].
The human RCC cell line SK-RC-42 was cultured by
employing the sphere culture method for enriching
CSCs/TICs [72]. Initially, SK-RC-42 cells were main-
tained as a monolayer in DMEM/F12 with 10 % FBS.
Tumor spheres were cultured by growing cells as a
monolayer in serum-free DMEM/F12 with 20 ng/ml
EGF, 20 ng/ml basic FGF, and B27 supplements. After
7–10 days, the tumor sphere was collected using gravity
and was dissociated using 0.1 % trypsin and 1 mM
EDTA. The cells were passed through 40 μm nylon
mesh and plated at 1000 cells/ml in serum-free DMEM/
F12 as described earlier to produce clonal spheres. These
spheres were further tested for putative stem cell
markers such as CD24, CD44, CD105, and CD133.
However, expression of CD105 was observed in all cul-
tures, which corresponds with the previous finding by
Bussolati et al. [2] showing CD105+ cells as TICs. In
contrast, Zhang et al. [27] used the serum-free approach
to assess the tumor sphere-forming ability after artifi-
cially inducing EMT in RCC cell culture rather than
enriching the stemness properties in cell culture.
Conclusions
Multiparametric flow cytometry allows simultaneous
analysis of different cellular features with high perform-
ance and reliability. This method can be used to separate
cells of interest using expression markers or functional
properties through FACS [73]. However, isolation and
analysis of tissue samples with this method can cause ar-
tifacts that bias analysis [74]. New putative CSC/TICmarkers on the basis of surface expression in RCC cells
are under investigation. However, the reliability of CSC/
TIC markers in cancer research is still under debate
[75]. CSCs/TICs accumulated mutations in some of the
key signaling pathways, such as Wnt, Notch, and Hedge-
hog, that are mainly responsible for proliferation, apop-
tosis, cell cycle, repair, and other functional features
[76]. These genetic mutations trigger the tumor pheno-
type in normal stem cells. The cellular phenotype of
CSCs/TICs is transient and may vary during the develop-
ment and growth of in-vivo and in-vitro tumor culture.
Phenotypic changes that occur in in-vitro experimental
conditions also influence marker expression analysis and
detectability [77]. It has often been observed that some
marker proteins on the cell surface are sensitive to enzym-
atic digestion, particularly when cells need to be digested
before flow cytometry analysis [78]. Optimization of cul-
turing conditions is therefore necessary before isolation
and flow cytometry analysis. The choice of protease for
cell detachment is highly important for preserving the an-
tigenicity of individual cell surface markers for the identifi-
cation and sorting of CSCs/TICs [79]. An alternative to
trypsin is the use of Accutase, which is often viewed as be-
ing gentler for cellular detachment without the need for a
neutralizing solution.
CSCs/TICs often express ABC transporter proteins,
which enables use of DNA dyes such as Hoechst 33342
and Rh123 and the use of flow cytometry to identify
them as a “side population” [80]. When SP cells are
identified though staining, it is not clear whether they
represent the entire pool of CSCs in a tumor or just part
of it [73]. Differences in staining protocols may contrib-
ute to such discrepancies as the cell staining incubation
time, dye concentrations, cell densities, and different
gating strategies [81, 82]. Cell line-specific properties
also influence analysis [82]. Proper measures should
therefore be taken before adjusting the staining protocol.
There are variations that exist in the Hoechst 33342
staining protocol, and these variations therefore have to
be taken into consideration before interpreting data [81].
Different manufacturers offer variation in the final work-
ing concentration of Hoechst 33342 dye. Commonly, the
final working concentration varies from 0.1 to 10 μg/ml
Hoechst 33342 dye in a reaction tube. The correlation
between the incubation time and the Hoechst dye con-
centration is crucial for dye uptake kinetics in character-
izing CSCs [83]. These variations in protocol probably
lead to skepticism and uncertainty about the accuracy of
the Hoechst method for stem cell detection [73].
Analysis of stem cell features though the SP, ALDH, or
cell surface markers exclusively have limitations to iden-
tify CSCs/TICs in RCC. For instance, Bussolati et al. [2]
analyzed the cell surface marker CD105 alone as CSCs/
TICs in RCC tissues. On the other hand, SP analysis
Khan et al. Stem Cell Research & Therapy  (2015) 6:178 Page 9 of 11alone was sufficient to identify CSC/TIC phenotypes in
the RCC cell line 769-P [47]. Combining several markers
is therefore suggested. A combination of SP or ALDH
analysis with cell surface markers such as CD105,
CD133, or CXCR4 in investigating CSCs/TICs in RCC
will provide significant and valuable data in the future.
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